333 filings
8-K
INMB
INmune Bio Inc
13 Jun 24
Departure of Directors or Certain Officers
4:05pm
8-K
INMB
INmune Bio Inc
30 May 24
Other Events
4:00pm
DEF 14A
INMB
INmune Bio Inc
Definitive proxy
29 May 24
4:05pm
8-K
INMB
INmune Bio Inc
23 May 24
Amendments to Articles of Incorporation or Bylaws
4:00pm
8-K
INMB
INmune Bio Inc
16 May 24
Departure of Directors or Certain Officers
4:00pm
8-K
q5vhrv02
10 May 24
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a
7:46pm
8-K
u8sete
30 Apr 24
Other Events
4:01pm
8-K
rsjng
26 Apr 24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:28pm
424B5
hssf2u
26 Apr 24
Prospectus supplement for primary offering
4:26pm
8-K
g6tlfrvplncfqap ae
25 Apr 24
Other Events
4:35pm
8-K
g8illasvrsfh576yk
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
424B5
o1qrr vyp0nj
22 Apr 24
Prospectus supplement for primary offering
5:09pm
8-K
jswf82tgww1i i8
9 Apr 24
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
4:58pm
8-K
uau re0qy2
29 Mar 24
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
4:01pm
8-K
zl5zij
27 Mar 24
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
4:07pm
8-K
6fz9p7e6fg
30 Jan 24
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
8:02am